

Table of Contents

Foreword (by <i>T.J. Allen</i>)	VII
Foreword (by <i>J. Meier</i>).....	IX
Preface	XI
1 Independent Biopharmaceutical Companies and Their Specialization in Drug Discovery Technologies	1
1.1 Drug Discovery in Research and Development Pipelines	1
1.2 Growth Problems Generated by R&D Duration.....	14
1.3 Consequences of Human Genetic Research on Drug Discovery	20
2 Model Structure for High-Technology Firms and Its Dynamic Behavior in Start-Up Phases	33
2.1 Macro Structure for Entrepreneurial Management of Start-Ups.....	33
2.1.1 System Dynamics as Research Methodology	33
2.1.2 Advancement of a Novel Disease Target Technology as Phase Objective	42
2.1.3 Impacts of Entrepreneurial Confidence on Voluntary Leaving, Absorptive Capacity, and Corporate Planning Horizon.....	49
2.2 Micro Structure that Determines High-Technology Performance	59
2.2.1 Average Research Experience of Scientists.....	59
2.2.2 Diversity of Scientific Disciplines.....	69
2.2.3 Research Quality as Dependent on Understanding of Failures	75
2.3 Dynamic Behavior from Start-Up Model Experiments	79
2.3.1 Surprise Behavior of Technology Effectiveness.....	79
2.3.2 Start-Up Success as Determined by Conditions of Corporate Foundation.....	96
2.3.3 Policy Design to Accelerate Start-Up Success	111

3	Model Structure and Dynamic Behavior for High-Technology Firms in Transition to Growth Phases.....	127
3.1	Macro Structure for Contract Research	127
3.1.1	Scope of Transition Model, Boundaries, and Time Horizon	127
3.1.2	Feedback Structures for Growth and Growth Saturation.....	130
3.1.3	Principal-Agent Theory to Investigate Research Contracts.....	135
3.2	Micro Structure for Contract Research on Novel Disease Targets	142
3.2.1	Industry Demand for Research Contracts.....	142
3.2.2	Planning of Scientific Laboratory Personnel.....	148
3.2.3	Obsolescence/Irrelevance of Scientific Experience and Contract Research Funding	150
3.3	Dynamic Behavior from Transition Model Experiments	154
3.3.1	Simulation Studies on Corporate Transition.....	154
3.3.2	Attractiveness Fluctuations from Technology Effectiveness	162
3.3.3	Firm Value from Contract Research Funds	167
4	Economic Value Creation in Transition Phases: Access to Equity Capital	173
4.1	Value Creation from Drug Candidates in Collaborative R&D Pipelines	173
4.1.1	Flow of Drug Candidates Through Pipeline Phases	173
4.1.2	Present Value of Royalty Expectations from Drug Candidates	188
4.1.3	Capital Asset Pricing Model for Discount Rate Estimation	193
4.2	Simulation of Value Creation	197
4.2.1	Present Values of Pipeline Phases	197
4.2.2	Option Premium as a Complement to Present Value	202
4.2.3	Option Premium and Present Value for Investment Decisions	209
4.3	Equity Financing for Growth Phases.....	223
4.3.1	Fund-Raising Success as Determine by Value Creation in R&D	223

4.3.2 Attractiveness to Investors from Research Track Record and Collaborative Partnership.....	227
4.3.3 Sensitivity of Fund-Raising Success to Value Creation in R&D	233
5 Strategies for Growth Phases to Sustain Independence.....	237
Bibliography.....	239
Appendix 1: Parameter List for Start-Up Model.....	259
Appendix 2: List of Equations for Start-Up Model	261
Appendix 3: Parameter List for Transition Model.....	299
Appendix 4: A Dynamic Theory on Cost of Capital for Biotechnology Firms.....	301
1. Dependency of Cost of Capital on R&D Pipeline Phases	301
2. Leverage Concept to Explain Cost of Capital for Investment in R&D Projects	305
3. Consequences for Management Decisions.....	313
Index	323